Trial · NCT00525824
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in TC/HDL-C After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment | Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) | Percentage | MEAN | |
| SECONDARY | Percent Change in LDL-C After 6 Weeks Monotherapy | Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward) | Percentage | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00525824/outcomes